3 results
Cohort 1 - LN-145 monotherapy in patients who have progressed during or following systemic therapy for recurrent, metastatic, or persistent disease and Cohort 2 - LN-145 monotherapy in patients previously treated with an antiprogrammedcell death…
The primary objective:To demonstrate that CT-P10 is similar to Rituxan in terms of pharmacokinetics as determined by AUCtau and CmaxSS at Cycle 4 and maximum serum concentration at steady state The secondary objective:Efficacy: the primary endpoints…
The study is divided in two phases.The primary objective of phase I of the study is to evaluate the safety and toxicity of the infusion of ex vivo expanded UCB-NK cells, both with and without sc IL-2 following immunosuppressive conditioning therapy…